This concern was substantiated by a previous meta-analysis based on randomized controlled trials (RCTs), demonstrating that while PCSK9 inhibitors reduce the risk of major adverse cardiovascular events (MACE), non-fatal MI, and stroke, they do not significantly affect HF [17]. The gene discussed is PCSK9; the disease is hydrops fetalis.